BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19360146)

  • 1. Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic.
    Kopetz S
    Gastrointest Cancer Res; 2007; 1(4 Suppl 2):S37-41. PubMed ID: 19360146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.
    Xu KP; Yin J; Yu FS
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2832-9. PubMed ID: 16799022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation.
    Mugabe BE; Yaghini FA; Song CY; Buharalioglu CK; Waters CM; Malik KU
    J Pharmacol Exp Ther; 2010 Jan; 332(1):116-24. PubMed ID: 19797620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer.
    Buchanan FG; Gorden DL; Matta P; Shi Q; Matrisian LM; DuBois RN
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1492-7. PubMed ID: 16432186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
    Rao S; Larroque-Lombard AL; Peyrard L; Thauvin C; Rachid Z; Williams C; Jean-Claude BJ
    PLoS One; 2015; 10(2):e0117215. PubMed ID: 25658745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
    Jaganathan S; Yue P; Turkson J
    J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.
    Mao W; Irby R; Coppola D; Fu L; Wloch M; Turner J; Yu H; Garcia R; Jove R; Yeatman TJ
    Oncogene; 1997 Dec; 15(25):3083-90. PubMed ID: 9444956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation.
    Li Z; Hosoi Y; Cai K; Tanno Y; Matsumoto Y; Enomoto A; Morita A; Nakagawa K; Miyagawa K
    Biochem Biophys Res Commun; 2006 Mar; 341(2):363-8. PubMed ID: 16414009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular rationale of Src inhibition in colorectal carcinomas.
    Gargalionis AN; Karamouzis MV; Papavassiliou AG
    Int J Cancer; 2014 May; 134(9):2019-29. PubMed ID: 23733480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
    Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M
    Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular Ca2+, PYK-2, and p60(src).
    Keely SJ; Calandrella SO; Barrett KE
    J Biol Chem; 2000 Apr; 275(17):12619-25. PubMed ID: 10777553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation.
    Yamamoto K; Takahashi K; Shiozaki K; Yamaguchi K; Moriya S; Hosono M; Shima H; Miyagi T
    PLoS One; 2015; 10(3):e0120578. PubMed ID: 25803810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones.
    Dewar BJ; Gardner OS; Chen CS; Earp HS; Samet JM; Graves LM
    Mol Pharmacol; 2007 Nov; 72(5):1146-56. PubMed ID: 17686966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.